Compare iShares Global Tech ETF (IXN) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Tech ETF vs Zoetis Inc — how do they compare? iShares Global Tech ETF trades at $149.84 (market cap $10.03B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 3× iShares Global Tech ETF's market cap, and Zoetis Inc pays a 2.9% dividend while iShares Global Tech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Tech ETF for 47 Days and Zoetis Inc for 70 Days on average.
| IXN | ZTS | |
|---|---|---|
Market Cap | $10.03B | $30.20B |
Volume | 286,617 | 6,175,327 |
Sector | Sector/Thematic | Health |
52-Week High | $152.94 | $147.53 |
52-Week Low | $95.76 | $69.09 |
Typical Hold Time | 47 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IXN, the iShares Global Tech ETF, trades at $149.84, down 1.52% on the day but near its 52-week high of $151.40, indicating strong momentum. Technical signals are bullish overall, with moving averages supporting an uptrend, while oscillators remain neutral. Recent news highlights the ETF hitting new highs and trading at a high-teens P/E with a compelling long-term EPS growth outlook, though concentration and AI exposure pose risks.
The outlook for IXN is positive, driven by global tech diversification and AI growth opportunities, but investors face risks from portfolio concentration and market volatility. Wall Street sentiment is bullish, with analysts citing valuation compression and earnings potential as key catalysts for further gains.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
